KARL STORZ acquires AI software manufacturer Innersight Labs to enhance medical technology

KARL STORZ, a renowned family-owned MedTech company, has announced its acquisition of innovative software manufacturer Innersight Labs Ltd. (ISL), based in London. This acquisition marks a significant expansion for KARL STORZ, known for its advanced endoscopes and medical devices, as it delves deeper into innovative software solutions in the healthcare sector. The financial details of the purchase have not been disclosed.

ISL, a British company founded in 2015 by Oxford graduates Lorenz Berger, Eoin Hyde, and Matt Gibb, has developed a groundbreaking software product, Innersight3D. This software allows surgeons to create patient-specific 3D models from medical CT or MRI scans, enhancing the precision of surgical procedures. The AI-driven technology significantly reduces manual effort and cost per model, setting it apart from competing products in the market.

KARL STORZ Announces Strategic Acquisition of Innersight Labs to Advance AI in Surgery

Thriving innovation is part of the KARL STORZ DNA

Since its inception in 1945, KARL STORZ has been at the forefront of medical technology innovation, particularly in minimally invasive surgery. With over 8,800 employees, the company has consistently set new standards in the healthcare sector. Thorsten Molitor, Executive Vice President at KARL STORZ, emphasized the company’s commitment to pioneering in MedTech, particularly in software and robotics: “The research background that ISL brings to the table fits ideally with our vision, mission, and strategic goals.”

KARL STORZ and Innersight Labs combine forces

The integration of ISL into the KARL STORZ portfolio introduces a new AI-driven product, aligning with the company’s vision of advancing AI in laparoscopic and robotic imaging solutions. This acquisition signifies KARL STORZ’s dedication to incorporating AI into medical technology development, aiming to deliver safer and more effective instruments for patients.

Close cooperation with the KARL STORZ robotics entity

KARL STORZ VentureOne, a subsidiary focused on robotics, is also set to benefit from this acquisition. Stephan Abele, Managing Director of KARL STORZ VentureOne, expressed excitement about the potential advancements in robotic products with ISL’s AI expertise: “We are very much looking forward to the cooperation and to further growing together in this area.”

This acquisition is a strategic move for KARL STORZ, positioning the company at the forefront of AI application in medical technology and strengthening its role in the global healthcare industry.